EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry

Esmé Kamphuis, Celeste M Boesjes, Laura Loman, Marijke Kamsteeg, Inge Haeck, Anneke M T Van Lynden-van Nes, Klaziena Politiek, Liana F Van der Gang, Marlies De Graaf, Marjolein S De Bruin-Weller, Marie L A Schuttelaar

Acta Dermato-Venereologica · 2024

DOI: 10.2340/actadv.v104.19454 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Acta Dermato-Venereologica, 2024. Verfasst von Esmé Kamphuis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Medical Center Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Eczema, Pyrimidines, Sulfonamides. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Limited daily practice data on the effect of abrocitinib in patients with atopic dermatitis are available. The aim of this multicentre prospective study is to evaluate the effectiveness and safety of abrocitinib in patients with atopic dermatitis treated in daily practice. In a subgroup, the effectiveness of abrocitinib on hand eczema was evaluated. A total of 103 patients from the BioDay registry were included in the study: week 4 (n = 95), week 16 (n = 61) and week 28 (n = 39). At week 28, the Eczema Area and Severity Index (EASI)-50/75/90 was achieved by 81.8%, 57.6%, and 18.2%, respectively, and the weekly average pruritus numerical rating scale ≤ 4 by 62.9%. The effectiveness of abrocitinib was not significantly different between dupilumab non-responders and dupilumab-naïve patients/responders, and between upadacitinib non-responders and upadacitinib-naïve patients/responders. Mean ± standard deviation Hand Eczema Severity Index decreased from 27.4 ± 27.7 at baseline to 7.7 ± 12.1 at week 28 (n = 31). Thirty-two patients (31.1%) discontinued treatment due to ineffectiveness (n = 17), adverse events (n = 9) or both (n = 3). The most frequently reported adverse event was nausea (n = 28). In conclusion, abrocitinib is an effective treatment for atopic dermatitis and can be effective for patients with previous inadequate response to dupilumab or upadacitinib. Furthermore, hand eczema can improve in patients treated with abrocitinib for atopic dermatitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicEczemaPyrimidinesSulfonamidesHumansProspective StudiesRegistriesTreatment OutcomeSeverity of Illness IndexDouble-Blind Method

Substanzen

abrocitinibPyrimidinesSulfonamides

Autor:innen und Institutionen

  • Department of Dermatology, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Dermatology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Dermatology, Reinier de Graaf Gasthuis, Delft, The Netherlands.
  • Department of Dermatology, Meander Medical Center, Amersfoort, The Netherlands.
  • Department of Dermatology, Medical Center Leeuwarden, Leeuwarden, The Netherlands.

Zitieren

APA

Kamphuis, E., Boesjes, C. M., Loman, L., Kamsteeg, M., Haeck, I., Van Lynden-van Nes, A. M. T., Politiek, K., Van der Gang, L. F., De Graaf, M., De Bruin-Weller, M. S., & Schuttelaar, M. L. A. (2024). Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v104.19454

Vancouver

Kamphuis E, Boesjes CM, Loman L, Kamsteeg M, Haeck I, Van Lynden-van Nes AMT, et al. Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry. Acta Dermato-Venereologica. 2024. doi:10.2340/actadv.v104.19454

BibTeX
@article{Kamphuis2024,
  author = {Kamphuis, Esmé and Boesjes, Celeste M and Loman, Laura and Kamsteeg, Marijke and Haeck, Inge and Van Lynden-van Nes, Anneke M T and Politiek, Klaziena and Van der Gang, Liana F and De Graaf, Marlies and De Bruin-Weller, Marjolein S and Schuttelaar, Marie L A},
  title = {Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry},
  journal = {Acta Dermato-Venereologica},
  year = {2024},
  doi = {10.2340/actadv.v104.19454}
}
Kostenlos starten →